How MD. was paid
$1.7M in total for 2026, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Stock | Other | Total |
|---|---|---|---|---|
| Spyros Papapetropoulos, MD.President and Chief Executive Officer | $284,625 | $272,325 | $1,117,740 | $1,674,690 |
| Tim CunninghamChief Financial Officer | — | — | — | $325,894 |
What changed and why
- 1,674,690 was the CEO’s total compensation in 2026, compared with 923,533 in 2025.
- 1,117,740 was reported as the CEO’s all other compensation in 2026.
- 272,325 was the CEO’s 2026 stock-award compensation.
- 535,433 of severance represented twelve months of the former CEO’s base salary.
- 313,087 represented the former CEO’s target annual bonus paid as severance.
- 51,480 covered COBRA health benefit continuation premiums.
Other Neuphoria Therapeutics proxy statements
- 2025 proxy statement
Spyros Papapetropoulos, M.D., PhD paid $951,343 (+27% on the year).
Filed Oct 30, 2025
About this page
The figures were read out of the DEF 14A proxy statement on EDGAR by a language model and every number was then checked against the filing text; a figure that could not be found there is left out rather than shown. Totals follow SEC rules, which value stock and option awards at grant. Read the filing for footnotes and the compensation committee's full reasoning.